Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8 + and CD4 + Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress

Elizabeth F Krakow, MDMSc, Corinne Summers, MD, Ann Dahlberg, MD, Merav Bar, Melinda Ann Biernacki, Tanya Cunningham, MSc, Nicole Vartanian, MSc, Megan Hickner, RN, Colette Chaney, RN, Tsadik Habtetsion, PhD, Kyle Woodward, PhD, Robson Dossa, PhD, Michelle Brault, PhD, Marie Bleakley, MBBS MMSc PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-137726

Published: 2020

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies

Lauren Longo, Filippo Milano, MD PhD, Colleen Delaney, MD MSc, Marie Bleakley, MBBS, PhD MMSc, Lauri S Burroughs, MD, Brandon Hadland, MD PhD, Elisabetta Xue, MD, Laura Roberts, Soheil Meshinchi, MD PhD, Kanwaldeep K. Mallhi, MD, Monica Thakar, MD, K Scott Baker, MD MS, Corinne Summers, MD, Ann Dahlberg, MD

Blood (2019) 134 (Supplement_1): 4611.

https://doi.org/10.1182/blood-2019-126062

Published: 2019

Journal Articles

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Julie Rivers, MD, Colleen Annesley, MD, Corinne Summers, MD, Olivia Finney, PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2018-99-113744

Published: 2018

Journal Articles

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Francesco Ceppi, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Stephanie Rhea, BS, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Wen Yang, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Rebecca Gardner, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2018-99-110164

Published: 2018

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Corinne Summers, MD, Colleen Annesley, MD, Marie Bleakley, MBBS, PhD MMSc, Ann Dahlberg, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 967.

https://doi.org/10.1182/blood-2018-99-115599

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

Journal Articles

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Corinne Summers, MD, Alexandra Grier, Rebecca Gardner, MD, Colleen Delaney, MD MSc, Michael C Jensen, MD

Blood (2016) 128 (22): 1159.

https://doi.org/10.1182/blood.V128.22.1159.1159

Published: 2016

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

Journal Articles

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Reduces the Risk of Bacteremia after Myeloablative Cord Blood Transplant

Corinne Summers, MD, Filippo Milano, MD PhD, Ted A. Gooley, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 3860.

https://doi.org/10.1182/blood.V124.21.3860.3860

Published: 2014

Journal Articles

Lentiviral Transduction Of Notch Ligand Expanded Cord Blood HSC’s To Express a CD19-Specific CAR Generates NK and Myeloid Progeny With Antitumor Activity

Rebecca Gardner, MD, Corinne Summers, MD, Dan Weber, Michael C. Jensen, MD, Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 900.

https://doi.org/10.1182/blood.V122.21.900.900

Published: 2013

NARROW

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8 + and CD4 + Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Reduces the Risk of Bacteremia after Myeloablative Cord Blood Transplant

Lentiviral Transduction Of Notch Ligand Expanded Cord Blood HSC’s To Express a CD19-Specific CAR Generates NK and Myeloid Progeny With Antitumor Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only